Thomas Marron, MD, PhD, on the Next Steps in Phase 1 Trial Investigating PGV-001

Video

Marron discussed the next steps to a trial of PGV-001, specifically centered around determining the immunogenicity of vaccinated patients against their antigens.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork® at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 about the next steps in a phase 1 trial of PGV-001, focusing on the immunogenicity of the cohort of vaccinated patients against their antigens.

Transcription:

Right now, we’re in the process of measuring the immunogenicity, basically the degree to which we successfully vaccinated these patients against their antigens. And we’re also looking at subsequent biopsies from patients who did have recurrent disease after the vaccine to see if there [are] any changes in the epitopes that are present or the antigens that are present in those recurrent tumors. In the poster, we show some data demonstrating that we did successfully prime a T-cell response, both the CD4 and the CD8 T-cell responses, against the neoantigens with which we vaccinated. And we’re hoping to see similar results as we continue our immune monitoring of the blood samples from the remaining patients.

Reference:

Marron TU, Saxena M, Bhardwaj N, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB048.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content